ASTERA LABS, INC. Record quarterly revenue of $159.4 million, up 13% QoQ and 144% YoY Strong demand for PCIe scale-up and Ethernet scale-out in custom ASIC platforms PCIe 6 connectivity portfolio poised to ramp in leading GPU-based rack-scale systems starting in Q2 SANTA CLARA, …
— Total Revenue Growth of 9% to $413.4 Million; Organic Revenue Growth(1) of 10% — — Net Income of $24.9 Million and Diluted Earnings Per Share of $0.20; Adjusted Diluted EPS(2) Growth of 16% to $0.65 — — Adjusted EBITDA(3) Growth of 12% Year-Over-Year …
What Happened? Shares of online work marketplace Upwork (NASDAQ:UPWK) jumped 19% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat analysts' revenue and EBITDA expectations, with full-year EBITDA and EPS guidance also coming in ahead of Wall …
Constellation Energy reported worse-than-expected first-quarter earnings Tuesday but kept its 2025 guidance steady. Continue Reading View Comments
Net revenue of $425.2 million GAAP gross margin of 28.8%; Non-GAAP gross margin of 35.2% GAAP operating loss of 8.9%; Non-GAAP operating margin of 10.8% GAAP diluted net loss per share of $0.64; Non-GAAP diluted net income per share of $0.57 SAN JOSE, Calif., …
(PRNewsfoto/Revolve Group, Inc.) LOS ANGELES, May 6, 2025 /PRNewswire/ -- Revolve Group, Inc. (NYSE: RVLV), the next-generation fashion retailer for Millennial and Generation Z consumers, today announced financial results for the first quarter ended March 31, 2025. Co-Founder and Co-CEO Commentary "Our strong execution …
Total End of Period Subscribers of 3.4 million, including 135 thousand End of Period Clinical SubscribersRevenues of $186.6 million, down 9.7% vs. prior year period, including Clinical Subscription Revenues of $29.5 million, up 57.1% vs. prior year periodSubscription Revenues Per Paid Weeks up 4.8% …
LAS VEGAS, May 06, 2025--(BUSINESS WIRE)--Wynn Resorts, Limited (NASDAQ: WYNN) ("Wynn Resorts" or the "Company") today reported financial results for the first quarter ended March 31, 2025. Operating revenues were $1.70 billion for the first quarter of 2025, a decrease of $162.5 million from …
CRISPR Therapeutics AG -Initial CTX310™ Phase 1 clinical data demonstrates dose-dependent decreases in triglycerides (TG) and low-density lipoprotein (LDL), with peak reduction of up to 82% in TG and up to 81% in LDL, with a well-tolerated safety profile; presentation anticipated at a medical …
OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast …